IO Biotech Plummets 77.5% on FDA Rejection and Restructuring Shockwave: A Tale of Regulatory Setbacks and Strategic Overhauls

Summary
• FDA advises against BLA submission for Cylembio, citing IOB-013 trial's near-miss on statistical significance
• IO Biotech cuts 50% of workforce, incurring $1–1.5M restructuring charges in Q3 2025
• Stock plummets to $0.355, down 77.5% from $1.58 previous close, trading between $0.3234 and $0.48 intraday
• Company projects cash runway until Q1 2026 as it pivots to EU regulatory discussions and new trial design

IO Biotech’s stock has imploded following a regulatory setback that forced a drastic restructuring. The FDA’s rejection of its BLA submission path for Cylembio, coupled with a 50% workforce reduction, has triggered a 77.5% intraday plunge. With the stock trading near its 52-week low of $0.3234, the company now faces a high-stakes race to redesign its clinical strategy while navigating a razor-thin cash runway.

FDA Rejects BLA Path, Triggers 50% Workforce Cut
The FDA’s recommendation against submitting a Biologics License Application (BLA) for Cylembio, based on the IOB-013 trial’s near-miss on statistical significance for progression-free survival (PFS), has triggered a cascading sell-off. The trial showed improved PFS with Cylembio plus pembrolizumab but fell short of the threshold required for regulatory approval. This outcome forced IO Biotech to abandon its U.S. commercialization timeline and pivot to a new registrational study. The company’s immediate response—a 50% workforce reduction and $1–1.5 million restructuring charge—signaled a shift from growth to survival mode. With capital projected to last only until Q1 2026, the market interpreted this as a high-risk scenario, driving the stock to its 52-week low.

Technical Deterioration and ETF Correlation: A Bearish Playbook
• 200-day average: 1.254 (far below current price)
• RSI: 39.6 (oversold territory)
• MACD: -0.056 (bearish divergence)
• Bollinger Bands: Price at 0.355, near lower band (1.415)
• K-line pattern: Short-term bearish trend, long-term ranging

The technicals paint a dire picture for IOBT. The stock is trading near its 52-week low, with RSI in oversold territory and MACD in negative territory, suggesting further downside. The Bollinger Bands indicate extreme volatility, with the price near the lower boundary. Given the lack of options liquidity and the absence of leveraged ETFs, a short-term bearish strategy is warranted. Key levels to watch include the 0.3234 intraday low (52-week low) and the 0.3507 open. A breakdown below 0.3234 could trigger panic selling, while a rebound above 0.48 (intraday high) might signal a temporary bounce. Sector leader Amgen (AMGN) is up 0.35%, offering a contrast to IOBT’s collapse, but its performance is unlikely to offset IOBT’s sector-specific risks.

Backtest IO Biotech Stock Performance
We successfully pulled every trading‐day OHLC bar for IOBT (Nasdaq: IOBT.O) from 2022-01-03 through 2025-09-29 and isolated all dates on which the share price fell at least 78 % (either intraday high-to-low or low vs. the previous close). Unfortunately, the event back-test engine that would normally turn those dates into return statistics is throwing an internal library error (missing function convert_statistics ).What we can do next1. Quick manual inspection • I can simply give you the list of “-78 % plunge” dates we identified so that you can see where the extreme moves occurred. • I can also report the raw next-day and 5/10/20-day price performance around each event (calculated ad-hoc).2. Alternate automated route • We can switch to the strategy back-test engine instead: open a position at the market close on each plunge day and exit after a fixed holding period (e.g., 5 or 10 trading days, or any rule you prefer). This avoids the part of the code that is currently failing.3. Wait for the event back-test engine fix • If you prefer the formal event analysis (average event return curve, optimal holding period, etc.), we can pause until the bug is patched.Let me know which path you’d like to take (1, 2 with your preferred holding-period rule, or 3), and I’ll proceed immediately.

Survival Mode: IOBT’s Path Forward and Immediate Action Alerts
IO Biotech’s stock is in freefall, driven by regulatory rejection and operational restructuring. The company’s cash runway until Q1 2026 and its pivot to EU regulatory discussions offer a sliver of hope, but the immediate outlook remains bleak. Investors should monitor the 0.3234 support level and the 0.3507 open for potential short-term bounces. Meanwhile, sector leader Amgen (AMGN)’s 0.35% intraday gain highlights the contrast between IOBT’s struggles and broader biotech resilience. For now, the priority is to avoid further downside exposure: watch for a breakdown below $0.3234 or a regulatory pivot in Q4.